UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038045
Receipt number R000043367
Scientific Title Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Date of disclosure of the study information 2020/12/19
Last modified on 2019/12/26 19:45:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers

Acronym

Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers

Scientific Title

Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers

Scientific Title:Acronym

Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To investigate the effects of lactic acid bacteria on menopause-like symptoms, sleep and biomarkers after 8 weeks of ingestion.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Kupperman Kohnenki Shogai Index (KKSI) at 8 weeks ingestion

Key secondary outcomes

1. Swelling
2. Blood flow
3. Stiff shoulder VAS
4. QOL questionnaire (SF-36)
5. Pittsburgh Sleep Quality Index (PSQI-j)
6. OSA sleep inventory MA version
7. Heart rate / activity survey


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of test food anytime except before going to bed. Or ingestion of test food before going to bed.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

45 years-old <=

Age-upper limit

55 years-old >

Gender

Female

Key inclusion criteria

(1) Female older than 45 years and younger than 55 years
(2) Subjects who are aware of aging irregular menstruation, indefinite complaints and poor sleep
(3) Subjects who can appropriately conduct heart rate and activity surveys
(4) Subjects judged to be healthy by a doctor

Key exclusion criteria

(1) Subjects who can not properly collect hair, saliva and blood flow test
(2) Subjects with history, treatment history, medication, or health food intake affecting the assessment of climacteric symptoms
(3) Subjects with history, treatment history, medication, or health food consumption that affect sleep assessment
(4) Subjects who have passed more than one year after menopause
(5) Subjects who take excessive amounts of soybean products such as natto and soy beverages
(6) Subjects who take foods rich in lactic acid bacteria (yogurt, lactic acid bacteria beverages, etc.) at least three times a week
(7) Subjects who have undergone oophorectomy or hysterectomy
(8) Excessive smokers, alcohol addicts, and subjects with extremely irregular diets
(9) Subjects whose overall score of the Pittsburgh Sleep Questionnaire at the pre-examination is less than 3, or more than 10, or who are estimated to have sleep disorders such as insomnia from the answers
(10) Subjects whose BMI are 30.0 kg/m^2 or more
(11) Subjects who are awakened midway through external factors such as child crying at least twice a week
(12) Night and day shift worker or manual laborer
(13) Subjects who have under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease) and disease to affect the adrenal cortical hormone secretion
(14) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(15) Subjects who are judged as unsuitable for the study because of clinical test, anthropometric test and physical examination in pre-inspection
(16) Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies
(17) Subjects who are pregnant or lactating, or plan to become pregnant or lactate during the study
(18) Subjects who are judged as unsuitable for the study by investigator for other reasons

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Soichi
Middle name
Last name Tanabe

Organization

NISSIN FOODS HOLDINGS CO., LTD.
R&D Platform NISSIN Global Innovation Center

Division name

Health Science Research Office

Zip code

192-0001

Address

2100, Tobukimachi, Hachioji, Tokyo

TEL

042-696-7685

Email

soichi.tanabe@nissin.com


Public contact

Name of contact person

1st name Shinsuke
Middle name
Last name Tsuji

Organization

TTC Co., Ltd.

Division name

Clinical Research Planning Department

Zip code

150-0021

Address

Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo

TEL

03-5459-5329

Homepage URL


Email

s.tsuji@ttc-tokyo.co.jp


Sponsor or person

Institute

TTC Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

NISSIN FOODS HOLDINGS CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aisei Hospital Ueno Clinic Research Ethics Committee

Address

2-18-6, Higashiueno, Taitou-ku, Tokyo

Tel

03-6455-0880

Email

t.saito@ttc-smo.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 09 Month 12 Day

Date of IRB

2019 Year 09 Month 12 Day

Anticipated trial start date

2019 Year 09 Month 20 Day

Last follow-up date

2019 Year 12 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 18 Day

Last modified on

2019 Year 12 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043367


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name